Previous 10 | Next 10 |
PALO ALTO, Calif. , Dec. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the closing of its previously announced underwritten ...
Major benchmarks rebounded on Wednesday, lifted by new hope that a preliminary deal on trade between the U.S. and China might still be possible in the short run. Market participants also got some readings that made them more optimistic about the prospects for continued economic growth across the...
Gainers: Protagonist Therapeutics (NASDAQ: PTGX ) +63% . More news on: Protagonist Therapeutics, Inc., Arbutus Biopharma Corporation, Kodiak Sciences Inc., Stocks on the move, Read more ...
Shares of Kodiak Sciences (NASDAQ: KOD) were jumping 17.3% higher as of 11:16 a.m. EST on Wednesday following the drugmaker's announcement after the market closed Tuesday of the specific pricing of a public stock offering. Kodiak plans to sell 6 million shares at a price of $46 per share -- ...
Schmitt Industries (NASDAQ: SMIT ) +13% on $2M stock repurchase plan . More news on: Schmitt Industries, Inc., EyePoint Pharmaceuticals, Inc., Kodiak Sciences Inc., Stocks on the move, Read more ...
Kodiak Sciences (NASDAQ: KOD ) has priced its public offering of 6M common shares at $46.00 per share, for expected gross proceeds of ~$276M. More news on: Kodiak Sciences Inc., Healthcare stocks news, Stocks on the move, Read more ...
PALO ALTO, Calif. , Dec. 3, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering of 6,0...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has commenced an underwritten public offering of ...
Gainers: Kodiak Sciences (NASDAQ: KOD ) +70% . More news on: Kodiak Sciences Inc., ASLAN Pharmaceuticals Limited, Cortexyme, Inc., Stocks on the move, Read more ...
Shares of Kodiak Sciences (NASDAQ: KOD) were skyrocketing 85.8% higher as of 10:41 a.m. EST on Monday after rising as much as 146.5% earlier in the day. This huge jump was spurred by Kodiak's announcement that it was selling a capped 4.5% royalty right on potential global net sales of experi...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth...